
Combining regular exercise with GLP-1 therapy is estimated to generate, in the UK, around £2.7bn in economic and societal value over 10 years (Image: pexels.com)
Pairing GLP-1 therapy with regular, structured exercise improves long-term health outcomes, reduces downstream costs and generates positive economic returns.
The findings come from a white paper, titled From Weight Loss to Lasting Value: Structured Exercise and the Economics of GLP-1 Therapy. The paper analyses research that examined the long-term clinical and economic value of the use of structured exercise in tandem with GLP-1 treatments.
Developed by FTI Consulting’s Center for Healthcare Economics and Policy, the white paper compares impacts of GLP-1 therapy as a standalone obesity treatment with GLP-1 therapy combined with exercise.
In partnership with a multinational coalition of fitness sector organisations, the analysis used a health-economic model adapted across Australia, Canada, New Zealand, the United Kingdom, and the United States. Across all five countries studied, the analysis found that a combined approach supports improved long-term health outcomes, reduced healthcare costs, and produced positive economic returns.
Combining regular exercise with GLP-1 therapy is estimated to generate, in the UK, around £2.7bn in economic and societal value over 10 years and a 164% return on investment, rising to 717% and £13bn over 30 years.
For the US, the figures are even higher – US$120bn in economic and societal value over 10 years and a 496% return on investment, rising to 1,572% and US$393 bn over 30 years. The study also looked at three other countries (New Zealand, Canada and Australia) and in each exercise generated added value.
The benefits of structured exercise identified in the report include patients preserving muscle during weight loss; maintaining strength, mobility, and bone health; keeping more weight off over time and reducing weight regain after stopping medication. Exercise can also lower the risk of costly health events later on.
The findings suggest that, as GLP-1 use expands, exercise should play an essential role in helping patients and health systems maximise the long-term value from new generations of weight-loss drugs.
Following the publication of the report on 15 June, physical activity bodies in each of the five countres – ukactive, the Health & Fitness Association, the HFA Foundation, AUSactive, Exercise New Zealand and Fitness Industry Council of Canada – are calling on policymakers, payers, and healthcare systems to integrate structured exercise into GLP-1 treatment pathways.
Specifically, they want to see structured exercise, including strength training, to be recognised as an essential part of obesity care and exercise support being embedded into GLP-1 care models.
They also want to see referral pathways being built between healthcare providers and qualified exercise professionals and fitness facilities, patients having access to qualified exercise professionals and fitness facilities and for the outcomes being measured beyond weight loss – including through long-term health and economic value.
The call to action builds on a recent joint position statement signed by the participating fitness industry groups, the World Obesity Federation (WOF), and the World Federation of the Sporting Goods Industry (WFSGI), which emphasised the urgency of ensuring physical activity and nutrition are central to systems supporting the global roll-out of obesity medications.
Cameron Saunders, CEO of ukactive, said: “GLP-1 medications have the potential to be genuinely transformative, but to really achieve this potential fully they must be combined with structured exercise.
“This research shows what could be at stake if they are not: £2.7 billion in avoidable costs to the UK health system over the next 10 years alone.
“Our members are ready to be delivery partners – we have the facilities, the professionals and programmes to make it happen at scale.
“The evidence is clear and the bill for inaction is one that health systems cannot keep picking up.”
Greta Wagner, President and CEO (Interim) of the Health & Fitness Association and President of the HFA Foundation, added: “GLP-1 medications are rapidly changing obesity treatment, but weight loss alone is not the full measure of success. The health and fitness industry has long known that lasting wellness requires more than a number on a scale, it requires strength, function, and sustainable healthy life habits.
“This research confirms that exercise, especially strength training, helps patients sustain the benefits of GLP-1 treatment over time. It sends a clear message that exercise belongs at the center of GLP-1 care.”
To read the full white paper, click here.



